{"id":"NCT02143973","sponsor":"Trevi Therapeutics","briefTitle":"Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus","officialTitle":"An Open Label Extension Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2014-09","primaryCompletion":"2016-01","completion":"2016-01","firstPosted":"2014-05-21","resultsPosted":"2020-09-07","lastUpdate":"2025-05-21"},"enrollment":167,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Uremic Pruritus","Pruritus"],"interventions":[{"type":"DRUG","name":"nalbuphine HCl ER","otherNames":["nalbuphine"]}],"arms":[{"label":"nalbuphine HCl ER","type":"EXPERIMENTAL"}],"summary":"The primary objective of the study is to evaluate the overall safety of nalbuphine HCL ER tablets during a treatment period of up to 24 weeks.","primaryOutcome":{"measure":"Number and Percetage of Participants With Treatment Emergent Adverse Events (TEAEs)","timeFrame":"24 weeks","effectByArm":[{"arm":"Nalbuphine HCl ER","deltaMin":133,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":35,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":54,"n":167},"commonTop":[]}}